![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Increasing Subject Compliance in Pivotal Phase III Clinical Trials of Dolutegravir (DTG, S/GSK1349572) in HIV-Infected, ART-Naive Subjects
|
|
|
Reported by Jules Levin
Glasgow 2012 Nov 11-15
J Harris,1 M Bomar,2 M Campbell3
1GSK Research & Development, Stockley Park, UK; 2GSK Research & Development, Research Triangle Park, NC, USA; 3Healthcare Communications Group, El Segundo, CA, USA
![Glasgow1.gif](../images/111612/111612-4/Glasgow1.gif)
![Glasgow2.gif](../images/111612/111612-4/Glasgow2.gif)
![Glasgow3.gif](../images/111612/111612-4/Glasgow3.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|